Abstracts tagged "spondylarthritis and vaccines"

Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting
Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial
Anna Molto¹, Adrien Etcheto², Serge Poiraudeau³, Laure Gossec⁴, Pascal Claudepierre⁵, Martin Soubrier⁶, Françoise Fayet⁷, Daniel Wendling⁸, Philippe Gaudin⁹, Emmanuelle Dernis¹⁰, Sandrine Guis¹¹, Sophie Pouplin¹², Adeline Ruyssen-Witrand¹³ and Maxime Dougados¹⁴, ¹Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ²Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, ³Univ. Paris Descartes, PRES Sorbonne Paris, INSERM UMR-S 1153 et Institut fédératif de recherche sur le handicap, Paris, France, Paris, France, ⁴Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, ⁵Hôpital Henri Mondor, Créteil, France, ⁶Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁹Grenoble University Hospital, France, Grenoble, France, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹Rheumatology Department, CHU, Marseile, France, ¹²Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ¹³Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹⁴Paris Descartes University, Hôpital Cochin, Paris, France
Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…
Abstract Number: 2164 • 2018 ACR/ARHP Annual Meeting
IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases
Mégane Beurai-Weber Jr.¹, Audrey Jaussent², Guilhem du Cailar³, Marie-Christine Picot², François Roubille Sr.⁴, Jean-David Cohen⁵, Jacques Morel⁶, Jean Bousquet⁷, Pierre Fesler⁸, Bernard Combe⁹ and Claire Daien¹⁰, ¹Rheumatology Department, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ²Department of medical information, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University, MONTPELLIER, France, ⁵IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ⁸Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁹University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, ¹⁰Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France
Background/Purpose: EULAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].